Tempest Therapeutics, Inc. (NasdaqCM: TPST)
Health Care · Biotechnology · US
$0.62
-17.88% today · -94.1% 1Y
Tempest Therapeutics, Inc. (NasdaqCM: TPST) operates in the Biotechnology industry within the Health Care sector. The company is valued at $10.32M and employs 4 people.
Over the last twelve months the share price has lost 94.1%, trading between 0.62 and 11.15.
Tweenvest scores Tempest Therapeutics, Inc. across four factors: quality 25/100, value 42/100. Its strongest factor is value.
TPST price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.32M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.56
- Dividend yield
- —
- Beta (5Y)
- -1.71
- 52-week high
- $11.15
- 52-week low
- $0.62
- Avg volume (3M)
- —
- Shares outstanding
- 16.54M
- Employees
- 4
- Next earnings
- —
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
- ISIN
- US87978U2078
- Listed since
- Nov 12, 2012
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| CytoMed Therapeutics LimitedNasdaqCM: GDTC | $10.50M | $0.88 | -1.13% |
| Palatin Technologies, Inc.LSE: 0KF3 | $10.49M | $5.89 | +1.55% |
| Ceryvyn Therapeutics LimitedASX: CYV | $10.47M | AU$0.01 | -15.38% |
| Regentis Biomaterials Ltd.NYSEAM: RGNT | $10.47M | $1.49 | -6.88% |
| Phio Pharmaceuticals Corp.NasdaqCM: PHIO | $10.12M | $0.87 | -11.00% |
| Ensysce Biosciences, Inc.NasdaqCM: ENSC | $10.08M | $0.52 | -1.65% |
| China Regenerative Medicine International LimitedSEHK: 8158 | $9.89M | HK$0.26 | -17.74% |
| Theriva Biologics, Inc.NYSEAM: TOVX | $9.54M | $0.21 | -4.19% |
Figures last refreshed Oct 18, 2026.